{"analyses":[{"estimateComment":"A normal score \\<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.","groupDescription":"An overall 5% significance level was used to compare treatments with respect to both overall survival (OS) and PFS. A 4% and 1% level (2-sided) was used to independently test OS and PFS, respectively.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1154","paramType":"Normal score","paramValue":"-1.57","statisticalComment":"P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure, and prior oxaliplatin exposure (yes or no).","statisticalMethod":"Stratified log-rank test"},{"estimateComment":"A normal score \\<0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.","groupDescription":"The treatment effect on OS in the Mutant KRAS Efficacy Analysis Set was compared at the 4% level conditional on first demonstrating a significant OS treatment effect in the Wild-type KRAS Efficacy Analysis Set.","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.5503","paramType":"Normal score","paramValue":"-0.60","statisticalComment":"P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure, and prior oxaliplatin exposure (yes or no).","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.0","upperLimit":"16.0","value":"14.5"},{"groupId":"OG001","lowerLimit":"11.2","upperLimit":"14.2","value":"12.5"},{"groupId":"OG002","lowerLimit":"10.4","upperLimit":"13.3","value":"11.8"},{"groupId":"OG003","lowerLimit":"10.3","upperLimit":"12.4","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"294"},{"groupId":"OG002","value":"238"},{"groupId":"OG003","value":"248"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG000","title":"Wild-type KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG001","title":"Wild-type KRAS - FOLFIRI Alone"},{"description":"Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG002","title":"Mutant KRAS - Panitumumab Plus FOLFIRI"},{"description":"Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.","id":"OG003","title":"Mutant KRAS - FOLFIRI Alone"}],"paramType":"MEDIAN","populationDescription":"KRAS Efficacy Analysis Set","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}